Fulgent Genetics Company Insiders
| FLGT Stock | USD 30.65 0.65 2.17% |
Fulgent Genetics employs about 1.3 K people. The company is managed by 13 executives with a total tenure of roughly 9 years, averaging almost 0.0 years of service per executive, having 101.0 employees per reported executive. Breaking down Fulgent Genetics' management performance can provide insight into the firm performance.
| Ming Hsieh Chairman Chairman of the Board and Presidentident, CEO |
Fulgent Genetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0363) % which means that it has lost $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0392) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities.Fulgent Genetics Workforce Comparison
Fulgent Genetics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 36,674. Fulgent Genetics holds roughly 1,313 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.18. Fulgent Genetics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulgent Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulgent Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fulgent Genetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gao Hanlin over two months ago Disposition of 943 shares by Gao Hanlin of Fulgent Genetics at 21.4847 subject to Rule 16b-3 | ||
Gao Hanlin over three months ago Disposition of 1642 shares by Gao Hanlin of Fulgent Genetics at 18.37 subject to Rule 16b-3 | ||
Ming Hsieh over three months ago Disposition of 800000 shares by Ming Hsieh of Fulgent Genetics subject to Rule 16b-3 | ||
Paul Kim over three months ago Disposition of 1131 shares by Paul Kim of Fulgent Genetics at 20.72 subject to Rule 16b-3 | ||
Gao Hanlin over six months ago Disposition of 656 shares by Gao Hanlin of Fulgent Genetics at 20.5169 subject to Rule 16b-3 | ||
Ming Hsieh over six months ago Disposition of 2324 shares by Ming Hsieh of Fulgent Genetics at 16.46 subject to Rule 16b-3 | ||
Gao Hanlin over six months ago Disposition of tradable shares by Gao Hanlin of Fulgent Genetics at 17.35 subject to Rule 16b-3 | ||
Gao Hanlin over six months ago Disposition of 1636 shares by Gao Hanlin of Fulgent Genetics at 16.29 subject to Rule 16b-3 |
Fulgent Genetics Notable Stakeholders
A Fulgent Genetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fulgent Genetics often face trade-offs trying to please all of them. Fulgent Genetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fulgent Genetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ming Hsieh | Chairman of the Board and Presidentident, CEO | Profile | |
| Jian Xie | COO President | Profile | |
| Ray Yin | President Pharma | Profile | |
| Doreen Ng | Vice Compliance | Profile | |
| Lawrence MD | Chief Officer | Profile | |
| Brandon Perthuis | Chief Officer | Profile | |
| Jakub Sram | Vice Sales | Profile | |
| DABMG FACMG | Chief Director | Profile | |
| Paul Kim | Chief Officer | Profile | |
| Natalie Prescott | General Officer | Profile | |
| Ellen Tsui | Vice Resources | Profile | |
| Paul CPA | Chief Officer | Profile | |
| Elias Nyankojo | Chief Officer | Profile |
About Fulgent Genetics Management Performance
The success or failure of an entity such as Fulgent Genetics often depends on how effective the management is. Fulgent Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fulgent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fulgent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 645 people.
Please note, the imprecision that can be found in Fulgent Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fulgent Genetics. Check Fulgent Genetics' Beneish M Score to see the likelihood of Fulgent Genetics' management manipulating its earnings.
Fulgent Genetics Workforce Analysis
Traditionally, organizations such as Fulgent Genetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fulgent Genetics within its industry.Fulgent Genetics Manpower Efficiency
Return on Fulgent Genetics Manpower
| Revenue Per Employee | 215.9K | |
| Revenue Per Executive | 21.8M | |
| Net Loss Per Employee | 33.4K | |
| Net Loss Per Executive | 3.4M | |
| Working Capital Per Employee | 213.8K | |
| Working Capital Per Executive | 21.6M |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.